|
1
|
Krewski D, Andersen ME, Tyshenko MG, Krishnan K, Hartung T, Boekelheide K, Wambaugh JF, Jones D, Whelan M, Thomas R, Yauk C, Barton-Maclaren T, Cote I. Toxicity testing in the 21st century: progress in the past decade and future perspectives. Arch Toxicol 2019; 94:1-58. [DOI: 10.1007/s00204-019-02613-4] [Citation(s) in RCA: 124] [Impact Index Per Article: 24.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Accepted: 11/05/2019] [Indexed: 12/19/2022]
|
|
2
|
Anadón A. Perspectives in Veterinary Pharmacology and Toxicology. Front Vet Sci 2016; 3:82. [PMID: 27679801 PMCID: PMC5020047 DOI: 10.3389/fvets.2016.00082] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2016] [Accepted: 09/01/2016] [Indexed: 01/09/2023] Open
Affiliation(s)
- Arturo Anadón
- Department of Toxicology and Pharmacology, Faculty of Veterinary Medicine, Universidad Complutense de Madrid , Madrid , Spain
| |
Collapse
|
|
3
|
Palazzi X, Burkhardt JE, Caplain H, Dellarco V, Fant P, Foster JR, Francke S, Germann P, Gröters S, Harada T, Harleman J, Inui K, Kaufmann W, Lenz B, Nagai H, Pohlmeyer-Esch G, Schulte A, Skydsgaard M, Tomlinson L, Wood CE, Yoshida M. Characterizing “Adversity” of Pathology Findings in Nonclinical Toxicity Studies. Toxicol Pathol 2016; 44:810-24. [DOI: 10.1177/0192623316642527] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
The identification of adverse health effects has a central role in the development and risk/safety assessment of chemical entities and pharmaceuticals. There is currently a need for better alignment regarding how nonclinical adversity is determined and characterized. The European Society of Toxicologic Pathology (ESTP) therefore coordinated a workshop to review available definitions of adversity, weigh determining and qualifying factors of adversity based on case examples, and recommend a practical approach to define and characterize adversity in toxicology reports, to serve as a valuable prerequisite for future organ- or lesion-specific workshops planned by the ESTP.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Kosei Inui
- Ishihara Sangyo Kaisha, Ltd., Osaka, Japan
| | | | - Barbara Lenz
- Roche Pharmaceutical Research and Early Development, Basel, Switzerland
| | - Hirofumi Nagai
- Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan
| | | | - Agnes Schulte
- Federal Institute for Risk Assessment, Berlin, Germany
| | | | | | - Charles E. Wood
- Office of Research and Development, U.S. EPA, Research Triangle Park, North Carolina, USA
| | | |
Collapse
|